Recombinant human erythropoietin is effective in correcting erythropoietin-deficient anaemia after allogeneic bone marrow transplantation.
Two children affected by severe aplastic anaemia (SAA) underwent allogeneic bone marrow transplantation (BMT) using partially matched family donors. In both cases there was a successful engraftment of donor haemopoietic stem cells. However, after an initial erythropoietic recovery, 5 months following BMT both children became severely anaemic. Although multiple factors were responsible for anaemia, in both cases there was a markedly impaired erythropoietin response to anaemia, as indicated by the inappropriately low levels of serum erythropoietin (EPO). Treatment with recombinant human erythropoietin (rHuEPO) induced a sustained erythropoietic response with complete correction of anaemia. This pilot study suggests that rHuEPO can be effective in correcting long-lasting anaemia after marrow transplantation, characterized by inadequate erythropoietin production.
Locatelli
F
F
Clinica Pediatrica, Università di Pavia, I.R.C.C.S. Policlinico San Matteo, Italy.
Pedrazzoli
P
P
Barosi
G
G
Zecca
M
M
Porta
F
F
Liberato
L
L
Gambarana
D
D
Nespoli
L
L
Cazzola
M
M
D000740:Anemia / Q000097:blood / Q000188:drug therapy*; D000741:Anemia, Aplastic / Q000601:surgery; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002675:Child, Preschool; D004921:Erythropoietin / Q000097:blood / Q000172:deficiency* / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000627:therapeutic use
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin